Caliway Biopharmaceuticals Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Caliway Biopharmaceuticals Co. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

Caliway Biopharmaceuticals Co.: 10 sponsored US clinical trials, 1 recruiting.

Caliway Biopharmaceuticals Co. sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Subcutaneous Fat, with 1 trials.

Top-decile sponsor footprint

Caliway Biopharmaceuticals Co. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

NCT06303570
NOT YET RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974
NOT YET RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939
COMPLETED Phase 2

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

NCT06005441
COMPLETED Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

NCT05736107
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

NCT05836779
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

NCT05632926
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

NCT05387733
COMPLETED Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

NCT04897412
COMPLETED Phase 2

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

NCT05234736

Phase Distribution

PhaseTrial count
Phase 2 8
Phase 3 2

Therapeutic Areas

Subcutaneous Fat 1
Dercum's Disease 1
Cellulite 1

What is open in the Caliway Biopharmaceuticals Co. pipeline

1 recruiting of 10 indexed (10% open); 7 completed (70%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Subcutaneous Fat (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Caliway Biopharmaceuticals Co.: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Caliway Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Caliway Biopharmaceuticals Co.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Caliway Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Caliway Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Caliway Biopharmaceuticals Co. page

10 registered trials is a research-attention snapshot, not an endorsement of Caliway Biopharmaceuticals Co. or any single study.

  • 1 of Caliway Biopharmaceuticals Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Subcutaneous Fat is the condition Caliway Biopharmaceuticals Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Subcutaneous Fat trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Caliway Biopharmaceuticals Co. pipeline card: 10 registered trials from official public datasets.Report a data error.